Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lanoxicaps

Known as: GlaxoSmithKline Brand 2 of Digoxin 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
ObjectiveThis study investigated the effect of varenicline on the multiple-dose pharmacokinetics of digoxin.MethodsEighteen… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Highly Cited
2006
Highly Cited
2006
Phytochemical-mediated modulation of P-glycoprotein (P-gp) and other drug transporters may underlie many herb-drug interactions… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
2005
2005
Phytochemical‐mediated modulation of p‐glycoprotein (P‐gp) and other drug transporters may underlie many herb‐drug interactions… Expand
2004
2004
Summary(1) The mean cumulative urinary digoxin excretion over 8 days was compared in 8 healthy volunteers after single doses of… Expand
  • table 1
1997
1997
AIMS To study the effect of eprosartan, a nonbiphenyl tetrazole angiotensin II receptor antagonist, on digoxin pharmacokinetics… Expand
  • table 1
Review
1994
Review
1994
This 72‐year‐old white woman with diabetes mellitus (Type II) and ischemic cardiomyopathy was referred for evaluation on the day… Expand
1991
1991
The bioavailability of digoxin in solution (Lanoxicaps, 90–100 percent) is superior to that of Lanoxin tablets (60–80 percent) in… Expand
  • table 2
  • table 1
  • figure 1
  • table 3
1986
1986
The oral absorption of digoxin in tablet form has been reported to be reduced after cancer chemotherapy and radiation therapy… Expand
1981
1981
Ten healthy subjects took each of 6 different solutions of 0.5 mg digoxin in a study of the effect of different solvents on… Expand
1977
1977
1 Twice daily administration of 0.25 mg digoxin tablets (Lanoxin) or of 0.2 mg digoxin in solution in soft gelatin capsules… Expand